Comprehensive Long-Term Safety of Adalimumab from Eighteen Clinical Trials in Adult Patients With Moderate to Severe Plaque Psoriasis.

CONCLUSIONS: AE rates remained stable in this analysis of patients with psoriasis receiving adalimumab; no new safety signals were identified compared with earlier analyses. This article is protected by copyright. All rights reserved.
PMID: 30169904 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - August 31, 2018 Category: Dermatology Authors: Leonardi C, Papp K, Strober B, Thaçi D, Warren RB, Tyring S, Arikan D, Karunaratne M, Valdecantos WC Tags: Br J Dermatol Source Type: research